Relief Therapeutics Holding AG
RLFTD
Other OTC4.08
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jack Weinstein
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- BAtiment F2/F3 Geneva Switzerland 1202
- IPO Date
- Nov 23, 2021
- Website
- relieftherapeutics.com
- Similar Companies
- Business
- Relief Therapeutics Holding AG is a biopharmaceutical company primarily engaged in the development and commercialization of innovative therapies for the treatment of severe and life-threatening diseases. The company’s main products and services include pharmaceutical drug development with a focus on respiratory, cardiovascular, and inflammatory diseases; its pipeline features lead drug candidates such as Aviptadil, a synthetic form of vasoactive intestinal peptide (VIP), under development for respiratory distress syndromes including COVID-19 related ARDS and pulmonary arterial hypertension. Relief Therapeutics also provides development services related to peptide-based therapies and leverages its expertise in therapeutic peptides to target acute and chronic diseases. Relief Therapeutics operates primarily in Europe, with headquarters in Geneva, Switzerland. It was founded in 2009 and has since expanded its focus on biopharmaceutical innovation centered around niche, high-need therapeutic areas. The company targets healthcare providers, hospitals, and research institutions as its main customer base. Relief Therapeutics has established strategic partnerships to accelerate its drug development programs, optimizing clinical trial operations and regulatory pathways. In recent major company developments occurring within the last 1-2 years, Relief Therapeutics has launched key clinical trials for its lead product Aviptadil, progressing toward regulatory approvals in multiple jurisdictions. It has also expanded its strategic alliances with other pharmaceutical companies and research organizations to enhance its product pipeline and commercialization efforts. The company has strengthened its financial base through recent funding rounds aimed at supporting late-stage development and market entry phases. There have been no reported name changes or reorganizations, but operational intensifications have occurred in clinical development and geographic expansion efforts to better position the company in the global biopharma market. Overall, Relief Therapeutics Holding AG is positioned as a specialized biopharmaceutical entity developing advanced peptide-based therapeutics focused on respiratory and other acute medical conditions, supported by strategic collaborations and robust clinical activities, headquartered in Switzerland and founded in 2009.